Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The protections extend through at least 2035, with the potential for further extensions
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Germany will be the first launch market
Subscribe To Our Newsletter & Stay Updated